Lexeo Therapeutics Faces Market Skepticism Despite Positive PKP2 Gene Therapy Data
H.C. Wainwright maintains a Buy rating on Lexeo Therapeutics but slashes its price target, citing persistent market doubts over the company's PKP2 cardiomyopathy program despite encouraging early clinical results.